Mumbai: Indian pharmaceutical companies need to go for aggressive research and patent filing, like China and Japan, industry experts said.

"Our Indian companies are just beginning to realise that they also need an R&D department as merely quality control would not help. Unless spending on R&D is scaled up, it will be difficult to create new molecules.

"It is time to go for aggressive research and patent filing just like China and Japan," Deputy Controller of Patents & Designs, Intellectual Property Office, K S Kardam said at a workshop on 'Patenting Pharmaceuticals in India'.

The next stage of development for the Indian pharmaceutical sector lies in the aspect of value creation, for which intellectual property becomes indispensable, he said.

"Over the next few years, it is expected that the patent laws will provide impetus to the launch of patent-protected products," Krishna Sarma, a Member of Advisory Council of India of Drug Information Association (DIA) and Managing Partner at Corporate Law Group, said.

According to Raghavendra Lal Saha, Former Adviser & Head Science & Society Division, National Good Laboratory Practice (GLP), "Protection of patents is not an end in itself but a means of encouraging creativity, industrialisation and investment. If used judiciously, it has business advantage and implications. There is no doubt the patent system has a big role to play in the growth of the pharmaceutical industry."

Gabriel Kleiman, Assistant General Counsel, Pfizer Inc, USA said, "A patent system is supposed to be about creating more incentives for innovation but it is equally important that innovation reaches to the society."


Latest News from Business News Desk